At the 2023 ESMO_ASIA , the latest clinical results of Cadonilimab were presented, demonstrating its potential therapeutic effect on HCC and laying a solid foundation for the next wave of research.

FDA has accorded an expedited evaluation to the drug Tarlatamab, developed by Amgen, which is aimed at treating advanced-stage small cell lung cancer.

ROCK2 inhibitors are drugs targeting the ROCK2 enzyme, crucial in various cellular processes.

Maze Therapeutics has commenced the administration phase of its Phase 1 clinical evaluation of MZE829 to test subjects in good health.

Site-directed mutagenesis is a molecular biology technique that is used to make specific and intentional changes to the DNA sequence of a gene and any protein that it may encode.

1ST Biotherapeutics, Inc. breaks new ground as it initiates the first human trial stage I/II by administering FB849, to individuals with progressive solid cancers

TT-00434 is an irreversible, highly selective inhibitor of FGFR1, 2, and 3 with potent preclinical activity against tumors harboring FGFR aberrations.

C4 Therapeutics, Inc., a company developing targeted protein degradation drugs, has announced early results from its Phase 1/2 trial's initial dose-escalation stage. The trial evaluates CFT7455, a unique MonoDAC™ agent targeting IKZF1/3 proteins, for treating multiple myeloma and non-Hodgkin lymphomas.

Oligonucleotide drugs are a class of medications that are composed of short, synthetic pieces of DNA or RNA known as oligonucleotides.

Shattuck Labs Reveals Promising Early Results from Continual Phase 1 A/B Clinical Study of SL-172154 Combined with Azacitidine in Newly Diagnosed Advanced Myelodysplastic Conditions (HR-MDS) and TP53 Mutation-Positive Acute Myeloid Leukemia Patients.

On 2 Dec 2023, the updated results of these two studies with extended follow-up were presented in 2023 ESMO_ASIA.

Plexium has begun dosing in a Phase 1 trial for its oral drug PLX-4545, a molecular glue degrader targeting the previously "undruggable" transcription factor IKZF2, also known as Helios.